ClinicalTrials.gg
Not yet recruitingNCT07894328Updated Oct 26, 2026

A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer

A Phase 3 interventional study of HRS-6209 + Letrozole and Dalpciclib/Palbociclib + Letrozole/Anastrozole in Breast Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Oct 26, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,050
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Planned enrollment
19th of 159
1,050 · median 95
Started
2026
with 3 others
Phase 3
41 of 162
4 open now
Primary completion
2031-07
later than 36 of 38 live
Registered
163rd of 162
by date

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 19th largest by planned enrollment of the 159 interventional ones that give a count, is one of 4 that started in 2026, is one of 41 in phase 3, reaches primary completion later than 36 of the 38 other live ones, and was the 163rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of HRS-6209 in combination with letrozole compared with dalpciclib or palbociclib in combination with aromatase inhibitor in patients with advanced or metastatic breast cancer who have not received prior systemic treatment for advanced or metastatic disease.

Approximately half of the participants will receive HRS-6209 plus letrozole while the other half of participants will receive dalpciclib or palbociclib in combination with aromatase inhibitor.

The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female aged ≥ 18 and ≤ 75 years.
  • Premenopausal patients must meet the eligibility of LHRH agonist therapy during the study period.
  • Histological confirmation of breast cancer with evidence of locally advanced or disease. Locally advanced diseased is not amenable to surgical resection or radiation therapy with curative intent.
  • Untreated with any systemic anticancer therapy for their locally advanced or metastatic disease. Patients received prior standard (neo) endocrine therapy must meet the following criteria:

    1. Complete neoadjuvant or adjuvant endocrine therapy for at least 24 months without recurrence or metastasis during treatment and 12 months after completion of treatment
    2. CDK4/6 inhibitor therapy for at least 12 months, if used in the (neo)adjuvant phase, with no recurrence or metastasis during treatment or within 12 months after completion of treatment.
  • (ECOG) Performance Status of 0 or 1.
  • or non-measurable bone only disease as defined by version 1.1
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • In visceral crisis at risk of immediately life-threatening complications in the short term.
  • Inflammatory breast cancer.
  • Uncontrolled or untreated .
  • Individuals with a known history of allergy to any component of this medication.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,050 participants (estimated)

Study arms

  • Experimental
    Arm A: HRS-6209 + Letrozole

    Drug: HRS-6209 + Letrozole

  • Active comparator
    Arm B: CDK4/6 inhibitors+ Aromatase Inhibitor

    Drug: Dalpciclib/Palbociclib + Letrozole/Anastrozole

Interventions

  • DrugHRS-6209 + Letrozole

    Drug pages: HRS-6209 · Letrozole

    HRS-6209 + Letrozole

  • DrugDalpciclib/Palbociclib + Letrozole/Anastrozole

    Dalpciclib/Palbociclib + Letrozole/Anastrozole

This study also gives Palbociclib, Anastrozole. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)

    Time from the date of randomization to the date of the first documentation of objective progressive disease as determined by blinded independent central review (BICR) per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Overall Survival (OS)

    Time from the date of randomization to the date of death due to any cause.

    Time frame: Up to approximately 13 years

  2. Progression Free Survival (PFS) by Investigator

    Time from the date of randomization to the date of the first documentation of objective progressive disease as determined by investigator per RECIST v1.1, or death due to any cause, whichever occurs first

    Time frame: Up to approximately 4 years

  3. Second progression-free survival (PFS2)

    Time from randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.

    Time frame: Up to approximately 5 years

  4. Overall Response Rate (ORR)

    The percentage of participants who had a complete response (CR) or partial response (PR), as assessed by BICR per RECIST v1.1.

    Time frame: Up to approximately 4 years

  5. Clinical Benefit Rate (CBR)

    Percentage of participants who have a CR, PR, or stable disease maintained for ≥ 24 weeks after randomization (without subsequent anticancer treatment) per RECIST v1.1 .

    Time frame: Up to approximately 4 years

  6. Duration of Response (DOR)

    Time from the first occurrence of a documented objective response to the time of disease progression or death from any cause, whichever occurs first, as assessed by BICR per RECIST v1.1.

    Time frame: Up to approximately 4 years

  7. Incidence of treatment emergent treatment related adverse events/serious adverse events

    Incidence and severity of AEs/SAEs graded according to NCI CTCAE v6.0

    Time frame: Duration of the study approximately up to 13 years.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2031, 56 months later.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 56 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 26, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Jul 30, 2031
CompletionEst.
Sep 30, 2031
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07894328
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Jul 30, 2031 (estimated)
Completion
Sep 30, 2031 (estimated)
Last update
Oct 26, 2026

Study contacts

Xiaonan Sheng
Contact
xiaonan.sheng.xs6@hengrui.com
13524857678
Xinxin Yi
Contact
xinxin.yi@hengrui.com
18036618193

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HRS-6209 · Letrozole

Start the discussion